As physician shortages and burnout threaten the patient experience in oncology, The US Oncology Network works to scale ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
Although AI can support complex oncology decision-making, physician judgment remains critical to ensuring safe, ...
Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...
Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...
Fortis Hospital Manesar, today launched Fortis Cancer Institute, the first dedicated cancer institute in Manesar, marking a ...
Florida Cancer Specialists & Research Institute, LLC is again partnering with Research to Practice® for the Fifth Annual ...
EO1001 demonstrates up to ~40-fold greater potency than osimertinib in EGFR ECD-mutant tumor models EO4426 (tezacitabine) demonstrates selective targeting of DNA replication machinery and resistance ...
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Small Cap Growth ...
Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...
Post-spin-off, Alkermes (RemainCo) will retain its focus on significant unmet needs within neuroscience and driving the growth of its proprietary commercial products, and Richard Pops would continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results